Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide for Refractory/Relapsed PTCL
NCT02944812Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Change of Chidamide concentration within the serum at 12 hours and Change of Chidamide concentration within the cerebral-spinal fluid (CSF) at 4 hours. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02944812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944812.